Aclaris Therapeutics Inc
ACRS1.526USD
-0.004-0.26%
交易中 （美东）报价延迟15分钟
165.21M总市值
亏损市盈率 TTM
关于 Aclaris Therapeutics Inc 公司
Aclaris Therapeutics, Inc. 是一家临床阶段生物制药公司，专注于开发免疫炎症疾病的新型候选药物。该公司拥有一个多阶段候选药物组合，由强大的研发引擎提供支持，探索蛋白激酶调控。其部门包括治疗和合同研究。治疗部门专注于识别和开发疗法，以满足免疫炎症疾病的未满足需求，并提供其知识产权的许可。合同研究部门提供实验室服务。该公司的 KINect 药物发现平台与其临床前开发能力相结合，使其能够识别和推进其可能独立开发或与第三方合作开发的潜在候选药物。该公司的候选药物包括 ATI-1777、ATI-2138 和 Zunsemetinib。ATI-1777 是一种研究性局部软 Janus 激酶或 JAK 1/3 抑制剂。
公司简介
公司代码ACRS
公司名称Aclaris Therapeutics Inc
上市日期Oct 07, 2015
CEODr. Neal S. Walker
员工数量64
证券类型Ordinary Share
年结日Oct 07
公司地址701 Lee Road
城市WAYNE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编19087
电话14843247933
网址https://www.aclaristx.com/
公司代码ACRS
上市日期Oct 07, 2015
CEODr. Neal S. Walker
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
Mr. Kevin Balthaser
Mr. Kevin Balthaser
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Non-Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Hugh M. Davis, Ph.D.
Dr. Hugh M. Davis, Ph.D.
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Dr. Anand Mehra, M.D.
Dr. Anand Mehra, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. James (Jim) Loerop
Mr. James (Jim) Loerop
Chief Business Officer
Chief Business Officer
103.31K
+21.18%
Mr. Christopher P. Molineaux
Mr. Christopher P. Molineaux
Lead Independent Director
Lead Independent Director
57.96K
+9.02%
Mr. William Douglas Humphries
Mr. William Douglas Humphries
Independent Director
Independent Director
33.52K
+16.68%
Dr. Maxine Gowen, Ph.D.
Dr. Maxine Gowen, Ph.D.
Independent Director
Independent Director
21.75K
+28.26%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
17.32K
+38.27%
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Independent Director
Independent Director
13.96K
+52.29%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2018
业务USD
名称
营收
占比
Licensing
1.01M
69.42%
Laboratory Research Revenue
445.00K
30.58%
暂无数据
业务
地区
业务USD
名称
营收
占比
Licensing
1.01M
69.42%
Laboratory Research Revenue
445.00K
30.58%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
BML Capital Management LLC
13.16%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
Rock Springs Capital Management LP
4.66%
Other
58.93%
持股股东
持股股东
占比
BML Capital Management LLC
13.16%
Adage Capital Management, L.P.
8.89%
Vivo Capital, LLC
8.21%
The Vanguard Group, Inc.
6.15%
Rock Springs Capital Management LP
4.66%
Other
58.93%
股东类型
持股股东
占比
Investment Advisor
27.72%
Hedge Fund
27.24%
Venture Capital
18.30%
Investment Advisor/Hedge Fund
10.34%
Research Firm
3.75%
Individual Investor
2.69%
Pension Fund
0.39%
Other
9.57%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
321
97.92M
90.43%
-39.77M
2025Q1
348
97.22M
89.83%
-39.83M
2024Q4
345
91.46M
84.84%
-21.09M
2024Q3
339
54.07M
75.01%
-55.64M
2024Q2
343
56.87M
79.07%
-55.28M
2024Q1
324
57.53M
81.03%
-59.90M
2023Q4
334
60.83M
85.72%
-31.33M
2023Q3
329
72.95M
103.11%
-12.25M
2023Q2
327
74.07M
104.78%
-6.71M
2023Q1
338
74.82M
111.43%
+1.42M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BML Capital Management LLC
14.25M
13.16%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
9.63M
8.89%
--
--
Mar 31, 2025
Vivo Capital, LLC
8.89M
8.21%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
4.97M
4.59%
+644.99K
+14.91%
Mar 31, 2025
Rock Springs Capital Management LP
5.05M
4.66%
-1.16M
-18.66%
Mar 31, 2025
RA Capital Management, LP
4.67M
4.31%
--
--
Mar 31, 2025
Decheng Capital LLC
4.04M
3.73%
+1.78M
+78.31%
Mar 31, 2025
Millennium Management LLC
5.54M
5.12%
+1.41M
+34.08%
Apr 28, 2025
D. E. Shaw & Co., L.P.
2.94M
2.72%
-349.11K
-10.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.41M
2.22%
+1.34M
+125.34%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco NASDAQ Future Gen 200 ETF
0.44%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Schwab U.S. Broad Market ETF
0%
iShares ESG Aware MSCI USA Small-Cap ETF
0%
Schwab U.S. Small-Cap ETF
0%
查看更多
Invesco NASDAQ Future Gen 200 ETF
占比0.44%
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Schwab U.S. Broad Market ETF
占比0%
iShares ESG Aware MSCI USA Small-Cap ETF
占比0%
Schwab U.S. Small-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
